explore -WSS

explore

author：knowledge 2025-09-28 18:47:31 - browse：4

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Listen: More tumult at BIO & coercive care for sickle cell patients

WSS

Some in Scotland's Orkney Islands want to return to Norway after 550 years

3 killed, 8 injured in late

US ambassador visits Wall Street Journal reporter detained in Russia on charges of espionage

Fentanyl is making it harder to start addiction treatment

US judge blocks portions of new Florida elections law

Trump pressured former Arizona governor to overturn 2020 election results: Sources

leisure time

explore

hotspot

Moonlake's readout produced a cash windfall. Risks remain

H5N1 bird flu outbreak: Second human case reported, in Michigan

Medicare proposal to cover medical devices draws a mixed reaction

A timeline of the missing Titanic tourist submersible

Guidelines to prevent youth baseball injuries need more muscle

H5N1 virus can be tracked in retail milk, scientists say

Activists slam private health insurers over coverage restrictions

PlayStation controller and acoustic messaging: How the missing Titanic tourist sub works

Malaria cases in Florida and Texas: Here’s what you need to know

Trump pressured former Arizona governor to overturn 2020 election results: Sources

leisure time

Scrutiny of post

10 states plan to sue EPA over standards for residential wood

Citing H5N1 threat, CDC urges peak flu monitoring this summer

The Democratic Party promised to overhaul its primaries. Doing that has been anything but simple

EU climate chief is concerned over the expansion of the coal industry in China

As a primary care physician, here's how I hope to partner with AI

entertainment

hotspot

hotspot

leisure time